The authors are not aware of any potential conflicts that may bias their work. As far as the authors are aware, the study raises no ethical issues.
Spending on new drug development1
Version of Record online: 26 FEB 2009
Copyright © 2009 John Wiley & Sons, Ltd.
Volume 19, Issue 2, pages 130–141, February 2010
How to Cite
Adams, C. P. and Brantner, V. V. (2010), Spending on new drug development. Health Econ., 19: 130–141. doi: 10.1002/hec.1454
- Issue online: 4 JAN 2010
- Version of Record online: 26 FEB 2009
- Manuscript Accepted: 5 JAN 2009
- Manuscript Revised: 24 NOV 2008
- Manuscript Received: 14 MAY 2007
- drug development
This paper replicates DiMasi et al. (J. Health Econ. 2003; 22: 151–185; Drug Inf. J. 2004; 38: 211–223) estimates of expenditure on new drug development using publicly available data. The paper estimates that average expenditure on drugs in human clinical trials is around $27m per year, with $17m per year on drugs in Phase I, $34m on drugs in Phase II and $27m per year on drugs in Phase III of the human clinical trials. The paper's estimated expenditure on new drug development is somewhat greater than suggested by the survey results presented in DiMasi et al. (J. Health Econ. 2003; 22: 151–185; Drug Inf. J. 2004; 38: 211–223). The paper combines a 12-year panel of research and development expenditure for 183 publicly traded firms in the pharmaceutical industry with panel of drugs in human clinical trials for each firm over the same period. The paper estimates drug expenditure by estimating the relationship between research and development expenditure and the number of drugs in development for 1682 company/years (183 firms multiplied by the number of years for which we have financial and drug development information). The paper also estimates expenditure on drugs in various therapeutic categories. Copyright © 2009 John Wiley & Sons, Ltd.